BUSINESS● LOWJul 14 · Jul 14, 2026, 12:28 PM
Spero gets ex-China rights to Innovent’s antibody therapy for up to $1.1B
Seeking Alpha Tech
Spero has acquired ex-China rights to Innovent's antibody therapy in a deal potentially worth up to $1.1 billion. This represents a major business transaction in the biopharmaceutical sector.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESSnowIn Morocco, the beneficial legacy of the BNDE crisisJeune AfriqueBUSINESS25m agoAsian markets rally on lower yields and easing crude; BOJ lifts benchmark rateSeeking Alpha Tech